Frontiers in Immunology (Mar 2023)
Proteomics: Potential techniques for discovering the pathogenesis of connective tissue diseases-interstitial lung disease
- Yinlan Wu,
- Yinlan Wu,
- Yinlan Wu,
- Yanhong Li,
- Yanhong Li,
- Yanhong Li,
- Yubin Luo,
- Yubin Luo,
- Yubin Luo,
- Yu Zhou,
- Xiuping Liang,
- Xiuping Liang,
- Xiuping Liang,
- Lu Cheng,
- Lu Cheng,
- Lu Cheng,
- Tong Wu,
- Tong Wu,
- Tong Wu,
- Ji Wen,
- Ji Wen,
- Ji Wen,
- Chunyu Tan,
- Chunyu Tan,
- Chunyu Tan,
- Yi Liu,
- Yi Liu,
- Yi Liu
Affiliations
- Yinlan Wu
- Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
- Yinlan Wu
- Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
- Yinlan Wu
- Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, China
- Yanhong Li
- Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
- Yanhong Li
- Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
- Yanhong Li
- Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, China
- Yubin Luo
- Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
- Yubin Luo
- Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
- Yubin Luo
- Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, China
- Yu Zhou
- Department of Respiratory and Critical Care Medicine, Chengdu First People’s Hospital, Chengdu, China
- Xiuping Liang
- Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
- Xiuping Liang
- Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
- Xiuping Liang
- Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, China
- Lu Cheng
- Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
- Lu Cheng
- Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
- Lu Cheng
- Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, China
- Tong Wu
- Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
- Tong Wu
- Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
- Tong Wu
- Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, China
- Ji Wen
- Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
- Ji Wen
- Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
- Ji Wen
- Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, China
- Chunyu Tan
- Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
- Chunyu Tan
- Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
- Chunyu Tan
- Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, China
- Yi Liu
- Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
- Yi Liu
- Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China
- Yi Liu
- Institute of Immunology and Inflammation, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Chengdu, China
- DOI
- https://doi.org/10.3389/fimmu.2023.1146904
- Journal volume & issue
-
Vol. 14
Abstract
Interstitial lung disease (ILD) is one of the most serious lung complications of connective tissue disease (CTD). The application of proteomics in the past decade has revealed that various proteins are involved in the pathogenesis of each subtype of CTD-ILD through different pathways, providing novel ideas to study pathological mechanisms and clinical biomarkers. On this basis, a multidimensional diagnosis or prediction model is established. This paper reviews the results of proteomic detection of different subtypes of CTD-ILD and discusses the role of some differentially expressed proteins in the development of pulmonary fibrosis and their potential clinical applications.
Keywords
- proteomics
- interstitial lung disease
- connective tissue diseases-interstitial lung disease
- differentially expressed proteins
- rheumatoid arthritis
- systemic sclerosis
